Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus. Epithelium-on CXL uses a formulation that allows the riboflavin to penetrate the cornea without the need to remove the epithelium, the outer most layer of the cornea.

Condition or disease	Intervention/treatment	Phase
Progressive Keratoconus	Drug: Paracel 1; Drug: Paracel Placebo; Drug: Paracel 2 R0185; Device: KXL High Power System (2 J); Device: KXL High Power System (10 J)	Phase 3

Detailed Description:

Up to 275 study eyes with progressive keratoconus will be enrolled. Study eyes will be randomized in a 2:1 ratio to receive CXL treatment or sham/control treatment.The primary efficacy endpoint is a difference of ≥ 1 diopter between treatment groups in the mean change in Kmax from baseline to Month 6.

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	275 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase III, Multi-center Study to Evaluate the Safety and Efficacy of Epithelium-on Corneal Collagen Cross-linking in Eyes With Progressive Keratoconus
Actual Study Start Date :	March 30, 2018
Estimated Primary Completion Date :	June 30, 2020
Estimated Study Completion Date :	June 30, 2020

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Active Comparator: CXL Treatment Group; Study eye receives Paracel 1, Paracel 2 R0185 and irradiated using KXL High Power System (10 J)	Drug: Paracel 1; Two drops every 60 seconds for 4 minutes; Other Name: 0.250% riboflavin ophthalmic solution; Drug: Paracel 2 R0185; Two drops every 30 seconds for 6 minutes; Other Name: 0.185% riboflavin ophthalmic solution; Device: KXL High Power System (10 J); 30 mW/cm2 for 11 minutes 6 seconds with an on/off cycle of 1 second UVA on/1 second UVA off (total UVA does of 10 J/cm2); Other Name: UVA Irradiation
Sham Comparator: Sham Treatment/Control Group; Sham eye receives Paracel Placebo and irradiated using KXL High Power System (2 J)	Drug: Paracel Placebo; Two drops of Paracel Placebo every 60 seconds for 4 minutes followed by two drops every 30 seconds for 6 minutes; Other Name: 0.0% riboflavin ophthalmic solution; Device: KXL High Power System (2 J); 6 mW/cm2 for 11 minutes 6 seconds with an on/off cycle of 1 second UVA on/1 second UVA off (total UVA does of 2 J/cm2); Other Name: Ultraviolet-A (UVA) Irradiation

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Kmax [ Time Frame: 6 months ]
   Mean difference of at least 1 diopter in Kmax change from baseline between treatment groups

Secondary Outcome Measures :

1. Kmax [ Time Frame: 12 months ]
   Change from baseline in Kmax between treatment groups

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	12 Years to 55 Years (Child, Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. Be between 12 and 55 years of age, male or female, of any race;
2. Provide written informed consent and sign a HIPAA form. Subjects who are under the age of 18 (or have not yet reached the age of majority per local regulations) will need to sign an assent form as well as having a parent or legal guardian sign an informed consent
3. Ability to read English or Spanish to complete the NEI-VFQ 25 questionnaire;
4. Willingness and ability to follow all instructions and comply with schedule for follow-up visits;
5. For females capable of becoming pregnant, agree to have urine pregnancy testing performed prior to randomization of each study eye and prior to treatment of a cross-over eye; must not be lactating, and must agree to use a medically acceptable form of birth control for at least one week prior to the randomization visit, one week prior to treatment of a cross-over eye, and continue to use the method for one month following the last treatment. Acceptable forms for birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (e.g. hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);

6. Having topographic and clinical evidence of keratoconus defined as thefollowing:

   • Axial topography consistent with keratoconus
   • Maximum corneal curvature, as measured by Kmax of ≥ 47.00 D;
   • Presence of central or inferior steepening on the Pentacam topography map

   • Presence of one or more findings associated with keratoconus, such as

     1. Fleischer ring
     2. Vogt striae
     3. Corneal thinning
     4. Corneal scarring
     5. Scissoring of the retinoscopic reflex

7. Having a diagnosis of progressive keratoconus, defined as one or more of the following changes over a period of 18 months or less:

   1. An increase of ≥ 1.00 D in Kmax or simK
   2. An increase of ≥ 1.00 D in regular astigmatism on subjective manifest refraction
   3. A myopic shift (towards greater negative sphere) of 0.50 D or more on subjective manifest refraction or as evaluated by comparing eyeglass or contact lens prescriptions to current subjective manifest refraction [NOTE: subjects with a clear history of progression but without prior documentation may be screened and followed for a period of time to confirm and document progression]
8. BSCVA of ≥ 1 letter and ≤ 85 letters on ETDRS chart
9. Contact Lens Wearers Only: Removal of contact lenses is required for a 1 week period prior to the screening visit(s) and subject must agree to remain out of their contact lenses from the time of treatment until the 1-month visit is completed. A contact lens wearer is defined as someone who has worn contact lenses in the eye to be treated in the last 30 days.

Exclusion Criteria:

1. Contraindications, sensitivity or known allergy to the use of the test article(s) or their components;
2. If female, be pregnant, nursing or planning a pregnancy or have a positive urine pregnancy test prior to the randomization or treatment of either eye or during the course of the study;
3. Eyes classified as either normal, atypical normal, or keratoconus suspect on the severity grading scheme;
4. A history of previous corneal surgery, limbal relaxing incision procedure, or insertion of Intacs in the eye(s) to be treated;
5. Corneal pachymetry that is < 325 microns at the thinnest point measured by Pentacam in the eye to be treated;
6. Eyes which are aphakic, or eyes which are pseudophakic and do not have a UV blocking lens implanted;

7. Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example:

   • History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, corneal melt, corneal dystrophy, etc.);
   • Clinically significant corneal scarring in the cross-linking treatment zone that is not related to keratoconus or, in the Investigator's opinion, will interfere with the cross-linking procedure;
8. A history of delayed epithelial healing in the eye to be treated or a current condition that may interfere with or prolong epithelial healing;
9. Subjects with nystagmus or any other condition that would prevent a steady gaze during the treatment or other diagnostic tests;
10. A history of previous corneal cross-linking treatment in the eye to be treated;
11. Have used an investigational drug or device within 30 days of screening or be concurrently enrolled in another investigational drug or device trial within 30 days of the study.

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Gerry Lohan	781-895-7832	glohan@avedro.com

Locations

United States, California
Stanford University School of Medicine	Recruiting
Palo Alto, California, United States, 94303
Contact: Theresa Enriquez 650-498-4573 Tenriquez@stanfordhealthcare.org
Principal Investigator: Edward Manche, MD
United States, Florida
Bascom Palmer Eye Institute	Recruiting
Miami, Florida, United States, 33136
Contact: Maria Esquiabro 305-326-6508 esquiabro@med.miami.edu
Principal Investigator: Sonia Yoo, MD
United States, Massachusetts
Ophthalmic Consultants of Boston	Recruiting
Waltham, Massachusetts, United States, 02451
Contact: Joanne Berry 617-314-2703 jberry@eyeboston.com
Principal Investigator: Michael Raizman
United States, Minnesota
Chu Vision Institute	Recruiting
Bloomington, Minnesota, United States, 55420
Contact: Nic Jacobs 952-835-6379 nic.jacobs@chuvision.com
Principal Investigator: Y. Ralph Chu, MD
Minnesota Eye Consultants	Recruiting
Minnetonka, Minnesota, United States, 55305
Contact: Amanda Devers 952-567-6198 aldevers@mneye.com
Principal Investigator: Sherman Reeves, MD
United States, Ohio
Comprehensive EyeCare of Central Ohio	Recruiting
Westerville, Ohio, United States, 43082
Contact: Donna Coury 614-890-5692 dcoury@compeyecare.com
Principal Investigator: Kenneth Beckman
United States, Pennsylvania
Vantage Eye Care, LLC	Recruiting
Bala-Cynwyd, Pennsylvania, United States, 19004
Contact: Cathy Petrocella, COT 484-434-2606 CPetrocella@oppdoctors.com
Principal Investigator: Brandon Ayres
United States, South Carolina
Carolina Cataract and Laser Center	Recruiting
Ladson, South Carolina, United States, 29456
Contact: Margaret Bozic 843-797-3676 mbozic@carolinacataract.com
Principal Investigator: David Vroman, MD
United States, South Dakota
Vance Thompson Vision	Recruiting
Sioux Falls, South Dakota, United States, 57108
Contact: Keeley Puls 605-371-7065 keeley.puls@vancethompsonvision.com
Principal Investigator: John Berdahl, MD
United States, Texas
Slade and Baker Vision Center	Recruiting
Houston, Texas, United States, 77027
Contact: Chadisty M Pauly 713-626-5544 chad@visiontexas.com
Principal Investigator: Stephen G Slade, MD
Focal Point Vision	Recruiting
San Antonio, Texas, United States, 78209
Contact: Lisa Navarro 210-614-3600 ext 118 navarro@focalpointvision.com
Principal Investigator: James Lehmann, MD
United States, Utah
Hoopes Vision	Recruiting
Draper, Utah, United States, 84020
Contact: Michele Avila, OD 801-568-0200 mavila@hoopesvision.com
Principal Investigator: Majid Moshifar
United States, Virginia
See Clearly Vision Group	Recruiting
McLean, Virginia, United States, 22102
Contact: Jenny Suy 703-827-4125 jsuy@seeclearly.com
Principal Investigator: Khoa D Hoang

Sponsors and Collaborators

Avedro, Inc.

Investigators

Study Director:	Vineeta Belanger	Avedro, Inc.

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Avedro, Inc.
ClinicalTrials.gov Identifier:	NCT03442751 History of Changes
Other Study ID Numbers:	ACP-KXL-308
First Posted:	February 22, 2018
Last Update Posted:	January 16, 2019
Last Verified:	January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		Yes
Device Product Not Approved or Cleared by U.S. FDA:		Yes
Pediatric Postmarket Surveillance of a Device Product:		No

Additional relevant MeSH terms:

Keratoconus; Corneal Diseases; Eye Diseases; Pharmaceutical Solutions; Ophthalmic Solutions; Riboflavin; Vitamin B Complex	Vitamins; Micronutrients; Growth Substances; Physiological Effects of Drugs; Photosensitizing Agents; Dermatologic Agents